17+ hour, 21+ min ago  (513+ words) California, US AI start-up Profluent has signed a major alliance with pharma group Eli Lilly, worth up to $2. 25 billion, that will focus on gene-editing therapies. Profluent has attracted attention since its launch in 2022 for its technology platform, which has the…...

13+ hour, 49+ min ago  (267+ words) This was the case recently when I attended Google Cloud's NEXT event with colleagues. Industry events often showcase what technology can do. What stood out to me at NEXT was something more meaningful: what pharma must do next to keep…...

18+ hour, 15+ min ago  (480+ words) GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October. If approved, bepirovirsen " which has priority, fast-track, and breakthrough designations from the US regulator " will become a first-in-class…...

19+ hour, 30+ min ago  (461+ words) Novartis has started to show the effects of its patent cliff more strongly, with sales and profits falling in the first quarter of this year on generic competition. Net sales fell 5%, or 1% at constant currencies, to $13. 1 billion due to generic…...

20+ hour, 9+ min ago  (221+ words) At a time when AI dominates the conversation, the most powerful insights in healthcare research still come from genuine human connection. In this webinar, senior experts from Konovo will discuss why a people-centric approach " built on human expertise, trusted partnerships,…...

1+ day, 19+ hour ago  (452+ words) The launch of a new national research collaboration focused on Parkinson's disease has been announced." The Parkinson's disease Translational Research Collaboration (PD-TRC), funded by the National Institute for Health and Care Research (NIHR) and supported by four major charities, is…...

1+ day, 20+ hour ago  (558+ words) After downplaying persistent rumours for months, Sun Pharma has broken cover with an $11. 75 billion takeover agreement for Organon, boosting its presence in the US market and the biosimilars category. The $14-per-share deal for Organon " which was formed in 2021 as a…...

1+ day, 16+ hour ago  (575+ words) Intellia's president and chief executive John Leonard. Intellia Therapeutics has reported the first-ever phase 3 results with an in vivo gene-editing therapy, hereditary angioedema (HAE) therapy lonvoguran ziclumeran (lonvo-z), and moved ahead straight away with a rolling marketing application in the…...

1+ day, 16+ hour ago  (178+ words) Under the agreement, EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery, including but not limited to agency of record, market access, commercial and medical teams to support the company's strategy to make Ensacove available to more patients across the…...

1+ day, 19+ hour ago  (509+ words) Sky-high expectations for sales of Eli Lilly's new oral GLP-1 agonist Foundayo have been dented by initial data from IQVIA, which shows slower initial take-up for the drug compared to Novo Nordisk's first-to-market Wegovy pill. The data " revealed by analysts…...